Skip to main content

Day: February 24, 2026

Option Care Health Announces Financial Results for Fourth Quarter and Full Year 2025

BANNOCKBURN, Ill., Feb. 24, 2026 (GLOBE NEWSWIRE) — Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (year-over-year comparisons unless otherwise noted)Net revenue of $1,465.4 million, up 8.8% Net income of $58.5 million, down 2.7% GAAP diluted earnings per share of $0.37, up 5.7% Adjusted EBITDA of $126.0 million, up 3.7% Adjusted diluted earnings per share of $0.46, up 4.5% Repurchased $95 million of stock in the quarterFull Year 2025 Financial Highlights (year-over-year comparisons unless otherwise noted)Net revenue of $5,649.5 million, up 13.0% Net income of $207.6...

Continue reading

Cipher Digital Provides Fourth Quarter and Full Year 2025 Business Update

Rebrands to Cipher Digital to Reflect Strategic Shift Toward HPC Divested 49% Stake in Alborz, Bear, and Chief Mining Sites Secured Full Funding for Existing Data Center Developments Through High-Yield Bond Offerings Data Center Development on Track at Barber Lake and Black Pearl NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) — Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced its fourth quarter and full year 2025 financial results, with an update on its operations and business strategy. “Building on a transformative 2025, the fourth quarter reflected continued momentum as we advanced our evolution into a leading HPC data center development company,” said Tyler Page, Chief Executive Officer. “During the quarter, we upsized our initial lease with Fluidstack and Google and signed our first HPC lease with Amazon....

Continue reading

Rail Vision: Quantum Transportation Advancing Toward Quantum Hardware Integration

Quantum Transportation’s unique decoder is making another step forward by being validated in high-performance cloud environments  Ra’anana, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN) (“Rail Vision” or the “Company”), an early commercialization stage technology company focused on transforming railway safety and the rail data markets, announced today that its majority owned subsidiary Quantum Transportation Ltd. (“Quantum Transportation”), a quantum computing innovator, has successfully implemented its transformer-based neural decoder on the AWS cloud, marking a significant milestone toward real-world quantum applications within the transportation sector. Building on the recent unveiling of its transformer neural decoder, which outperformed classical quantum error correction (QEC) algorithms in simulations,...

Continue reading

GDS Announces Adjournments of Extraordinary General Meeting and Additional Shareholders Meetings to be Reconvened on March 10, 2026

SHANGHAI, China, Feb. 24, 2026 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that in accordance with its previous press release dated January 26, 2026 (the “Previous Disclosure”), an Extraordinary General Meeting of Shareholders (the “EGM”) was convened at Beijing Meeting Room, F5, Building C, Sunland International, No. 999 Zhouhai Road, Pudong, Shanghai, P.R.C. at 4:00 p.m. (China Standard Time) on February 24, 2026 (which is 3:00 a.m. (Eastern Time) on February 24, 2026). A meeting of the holders of the class A ordinary shares (the “Class A Shareholders Meeting”) was convened at the same place at 4:30 p.m. (China Standard Time) on February 24, 2026, a meeting of the holders...

Continue reading

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs A separate analysis of treatment patterns in metastatic hormone-sensitive prostate cancer suggest significant opportunity for increased guideline adherenceBasel, February 24, 2026 – Novartis today announced multiple US real-world studies delivering new insights across metastatic prostate cancer care. The analyses utilize data from Novartis’ PRECISION platform to evaluate Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) effectiveness and sequencing as well as real‑world treatment patterns in earlier metastatic disease. These studies will be presented at the ASCO Genitourinary Cancers Symposium on February...

Continue reading

Gilat Receives $39 Million in Orders for Sidewinder ESA Terminals

New orders for Linefit and Retrofit installations underscore rising global demand for Gilat’s advanced Multi Orbit ESA technology PETAH TIKVA, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that it has received $39 million in orders from a leading satellite operator for its electronically steered antenna (ESA) Sidewinder in-flight connectivity terminals, including both linefit and retrofit installations. Deliveries are expected over the next 12 months. These new orders of additional Sidewinder ESA terminals highlight the accelerating global shift toward ESA solutions as airlines and service providers work to meet rapidly growing demand for high quality in-flight broadband. With its...

Continue reading

Xometry Announces CEO Succession Plan

Sanjeev Singh Sahni to Succeed Randy Altschuler as CEO; Altschuler to Become Executive Chair NORTH BETHESDA, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, announced that effective July 1, 2026, Co-founder and Chief Executive Officer, Randy Altschuler, will transition to become the Executive Chair of the Board. Sanjeev Singh Sahni, Xometry’s current President, will succeed Altschuler as Chief Executive Officer and join the Board of Directors. “I co-founded Xometry in 2013 to digitize the global manufacturing market and our record 2025 results are a testament to how far we’ve come. With the company on a clear and increasingly profitable trajectory, this is the ideal time to transition our leadership from a position of maximum...

Continue reading

First Watch Restaurant Group, Inc. Announces Retirement of Chief Financial Officer Mel Hope and Transition Plan

BRADENTON, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (Nasdaq: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, announced today that Chief Financial Officer Mel Hope has informed the Company of his intent to retire later this year. The Company has commenced a process to identify his successor, considering both internal and external candidates. It is expected that Hope will remain as Chief Financial Officer until his successor is in place to ensure a seamless transition and serve as an advisor to the Company for a period thereafter. “Mel joined us with decades of experience and was invaluable in guiding our IPO process,” said Chris Tomasso, CEO and President of First Watch. “For nearly eight years, he has served as a steady hand and confidant...

Continue reading

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 million EMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102 millionRegulatory submission for SYFOVRE prefilled syringe planned for the first half of 2026 EMPAVELI franchise has strong momentum with successful launch in C3G and primary IC-MPGN, and pivotal trials underway in FSGS and DGF Cash and cash equivalents of $466 million as of December 31, 2025; projected revenues, cash, and cash equivalents expected to be sufficient to fund operations to profitability Management to host conference call today at 8:30 a.m. ETWALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results...

Continue reading

Xometry Reports Record Fourth Quarter and Strong Full Year 2025 Results

Q4 revenue increased 30% year-over-year to a record $192 million, driven by robust marketplace growth. Q4 marketplace revenue growth accelerated to 33% year-over-year, driven by strong enterprise growth and expanded networks of buyers and suppliers. Q4 gross profit increased 27% year-over-year to a record $75.2 million, driven by strong marketplace growth and marketplace gross margin expansion. Q4 Adjusted EBITDA improved $7.3 million year-over-year to Adjusted EBITDA of $8.4 million, driven by expanding marketplace gross margin and strong operating expense leverage. Strong operating results were driven by consistent execution across growth initiatives: expanding buyer and supplier networks, driving deeper enterprise engagement, further expanding the marketplace platform, growing internationally, and enhancing services offerings.NORTH...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.